EMD Millipore, the Life Science division of Merck KGaA of Germany, today opened its state-of-the-art Biopharmaceutical Technical and Training Center in Shanghai, China. The 28,000 square foot facility will provide support, training and validation services to EMD Millipore's biopharmaceutical customers with operations in China.
"We are responding to China's commitment to strengthen regulatory requirements designed to ensure drug safety," said Jean-Paul Mangeolle, Head of EMD Millipore's Process Solutions business. "Our new Biopharmaceutical Technical Center is unique in that we can support and even train our pharmaceutical customers to meet the new Chinese and global regulations. Today we have taken a significant step not only expanding our 30 years of local offerings in China, but also to support the effort to produce safe, quality drugs in this important and fast growing region." Mangeolle was joined by a number of officials from the Chinese SFDA at today's opening ceremonies as well as representatives of Peking University. Both institutions will utilize EMD Millipore's new Technical Center for training courses specifically created for GMP training and Aseptic process manufacturing.
EMD Millipore's Shanghai Biopharmaceutical Technical Center is located in Zhangjiang Hi-Tech Park and will support area biopharmaceutical manufacturers. The facility will allow local and regional customers to investigate, explore and optimize their upstream and downstream processes as well as environmental monitoring processes with the support of EMD Millipore's local, regional and international experts.
EMD Millipore operates similar facilities in Singapore, Japan, India, France, North America and Brazil.